Journals / Turkish Neurosurgery / 2019 / Cilt: 29 - Sayı: 2

The Influence of Unilateral Subthalamic Deep Brain Stimulation on the Quality of Life of Patients with Parkinson’s Disease

Pages
194–204
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Different correlations between the improvements of separate UPDRS scores on PDQ-39dimensions require future studies in larger study groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: To assess the health-related quality of life (HRQoL) with the Parkinson’s Disease Questionnaire 39 (PDQ-39) after unilateralsubthalamic deep brain stimulation (STN DBS) and to identify correlations between the changes in UPDRS (Unified Parkinson’sDisease Rating Scale) scores and separate PDQ-39 QoL dimensions and PDQ summary index (SI) score at short-term follow-up(FU1) and long-term follow-up (FU2).MATERIAL and METHODS: We evaluated 33 patients with PD after unilateral STN DBS.
📊
Key Findings & Data:All patients were assessed at baselineand at FU1 and at FU2.
💡
Conclusion & Impact:Different correlations between the improvements of separate UPDRS scores on PDQ-39dimensions require future studies in larger study groups.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

AIM: To assess the health-related quality of life (HRQoL) with the Parkinson’s Disease Questionnaire 39 (PDQ-39) after unilateralsubthalamic deep brain stimulation (STN DBS) and to identify correlations between the changes in UPDRS (Unified Parkinson’sDisease Rating Scale) scores and separate PDQ-39 QoL dimensions and PDQ summary index (SI) score at short-term follow-up(FU1) and long-term follow-up (FU2).MATERIAL and METHODS: We evaluated 33 patients with PD after unilateral STN DBS. All patients were assessed at baselineand at FU1 and at FU2. HRQoL levels were determined by applying PDQ-39 and PD progression was evaluated by parts I-IV of theUPDRS.RESULTS: All dimensions of PDQ-39 as well as PDQ-39 SI score were highly significantly improved at FU1. The same improvementswere mostly visible at FU2 except for psychosocial functioning. The PDQ-39 SI score was reduced by 40 % (p<0.01) at FU1 and by25 % (p<0.01) at FU2. A significant reduction between the UPDRS baseline scores and the UPDRS follow-up scores was noticedfor medication off and on conditions under unilateral STN DBS. Interestingly, we did not find strong positive correlations betweenthe improvements of the UPDRS scores and individual PDQ-39 dimensions as well as PDQ-39 SI score.CONCLUSION: Improvements in PDQ-39 dimensions and PDQ-39 SI score are maintained at FU1 and except for the aspectsof psychosocial functioning at FU2. Different correlations between the improvements of separate UPDRS scores on PDQ-39dimensions require future studies in larger study groups.

🔖

Cite This Article

SOBSTYL, M., PASTERSKI, T., MICKA, G. Y. B. K., ALEKSANDROWICZ, M., SKI, A. Z. (2019). The Influence of Unilateral Subthalamic Deep Brain Stimulation on the Quality of Life of Patients with Parkinson’s Disease. Turkish Neurosurgery, Cilt: 29 - Sayı: 2, 194–204. https://ajindex.com/articles/405281

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Alberts JL, Hass CJ, Vitek JL, Okun MS: Are two leads always better than one: An emerging case for unilateral subthalamic deep brain stimulation in Parkinson’s disease. Exp Neurol 214(1):1-5, 2008 2. Amara AW, Standaert DG, Guthrie S, Cutter G, Watts RL, Walker HC: Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson’s disease. Parkinsonism Relat Disord 18(1):63-68, 2012 3. Aviles-Olmos I, Kefalopoulou Z, Tripoliti E, Candelario J, Akram H, Martinez-Torres I, Jahanshahi M, Foltynie T, Hariz M, Zrinzo L, Limousin P: Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson’s disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry 85(12):1419-1425, 2014 4. Daniels C, Krack P, Volkmann J, Raethjen J, Pinsker MO, Kloss M, Tronnier V, Schnitzler A, Wojtecki L, Bötzel K, Danek A, Hilker R, Sturm V, Kupsch A, Karner E, Deuschl G, Witt K: Is improvement in the quality of life after subthalamic nucleus stimulation in Parkinson’s disease predictable? Mov Disord 26(14):2516-2521, 2011 5. Defer GL, Widner H, Marié RM, Rémy P, Levivier M: Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 14(4):572-584, 1999 6. Drapier S, Raoul S, Drapier D, Leray E, Lallement F, Rivier I: Only physical aspects of quality of life are significantly improved by bilateral subthalamic stimulation in Parkinson’s disease. J Neurol 252(5):583-588, 2005 7. Erola T, Karinen P, Heikkinen E, Tuominen J, Haapaniemi T, Koivukangas J, Myllylä V: Bilateral subthalamic nucleus stimulation improves health-related quality of life in Parkinsonian patients. Parkinsonism Relat Disord 11(2):89-94, 2005 8. Germano IM, Gracies JM, Weisz DJ, Tse W, Koller WC, Olanow CW: Unilateral stimulation of the subthalamic nucleus in Parkinson disease: A double-blind 12-month evaluation study. J Neurosurg 101(1):36-42, 2004 9. Hamani C, Richter E, Schwalb JM, Lozano AM: Bilateral subthalamic nucleus stimulation for parkinson’s disease: A systematic review of the clinical literature. Neurosurgery 56(6):1313-1324, 2005 10. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181-184 1992 11. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N: The Parkinson’s Disease Questionnaire (PDQ-39): Development and validation of a Parkinson’s disease s